Follow us :
日本デスク
Site en français
Conseils en Propriété Industrielle / European Patent and Trademark Attorneys
PARIS
LYON
RENNES
MONTPELLIER
GRENOBLE
CAEN
TOULOUSE
MUNICH
Client Login
News
Events
In France and abroad
Legal News
Current IP News
Press Room
Press Releases
INFORMATION COVID-19
Expertise
Patents
Life Sciences and Chemistry
IT / Mechanics / Physics
Focus on our EP Practice
Unitary Patent
Trademarks & Designs
Our expertise
Contracts, IP valuation & Data
Drafting of your contracts
IP asset valuation
GDPR compliance
IP Intelligence
Patentability Study
Freedom to operate
Anticipating developments
For the last 80 years, we have been assisting our clients in protecting, developing and defending their innovations and creations.
Training
IP TRAINING
IP Academy
5-day seminar
Publications
Last Published
Current IP News
published by our IP Attorneys
Search for a publication
All our articles organised
by theme, author, IP rights
Focus on
Discover a selection of our publications arranged by topic.
IPON Newsletter
Read our latest newsletter
Team
Partners
Our team
Find your contact among our employees
REGIMBEAU's Network
Our network of International Associates and our involvement in Professional Organisations
日本デスク
Japan Desk
Careers
Join us
Discover our current employment offers and send your application
Contact us
Paris
Lyon
Rennes
Montpellier
Grenoble
Caen
Toulouse
Munich
Home
>
Team
>
Our team
>
CV
Our team
Patents - Life Sciences & Chemistry
Frédérique FAIVRE PETIT
Barbara CASADEWALL
Anne BOGARD BOUTARIC
Stéphanie CELAIRE
Emmanuelle LEVY
Philippe BESSIERE
Armelle LEONARD
Nicolas BOUQUIN
Soizic GUINDEUIL
Cécile PUECH
Margaux BERETTA
Isabelle BOSSER
Amandine CARRER
Lazarina CHOISNEL
Gabrielle FAURE-ANDRE
Raphaëlle GILLET
Marion GIZZI
Sara HAINES
Ludovic LE GUEN
Lionel MORVAN
Morgane RIEANT
Aurélia VAVASSEUR
Lucile VERNOUX
Patents - IT/Mechanics/Physics
Trademarks & Designs
Contracts, IP Valuation & Data
IP Intelligence
IP Administration
Search by name
Sara HAINES, Ph.D
US Patent Agent
Life Sciences & Chemistry Department
AGENCIES:
LYON
Email: haines@regimbeau.eu
Tel: +33 4 72 83 85 70
Languages:
Education
Bachelor of Science in Microbiology and Chemistry (Oregon State University, USA)
MS in Sciences and Technologies (Université Pierre et Marie Curie, Paris VI)
Ph.D in Microbiology (Université de Lyon)
CEIPI Graduate (Distinction in “Patents”)
Background
After five years research experience in the pharmaceutical industry and an initial experience in an IP Law firm, Sara HAINES joined REGIMBEAU in 2016.
Technical and scientific fields
Agronomy, Molecular and cellular biology, Biochemistry, Medical devices, Genetic engineering, Immunology, Microbiology, Vaccinations
Recent contributions and participations
Lyon
CLARA Forum
Participation of
Lucile VERNOUX
and
Sara HAINES
at CLARA Cancer Research Forum.
4th April 2019
Recent Publications
35 USC § 101: Further clarification of patent subject-matter eligibility.
By
Sara HAINES
, US Patent Agent.
Two recently issued USPTO memorandums further clarify aspects of patent subject-matter eligibility under 35 USC § 101. The Vanda memo1 specifies methods of treatment that should be considered to be patent eligible under step 2A of the Alice/Mayo test2 thereby avoiding any further analysis under step 2B, while the Berkheimer memo3 states that examiners must provide substantiated evidence when additional claim elements are considered to represent well-understood, routine, conventional activity in support of 35 USC § 101 rejections under step 2B.
Published on: 30th Oct 2018
Patent
Patentability of Biological Material
Biomarkers
Fields
Patent
Know-how
IP Prosecution
Portfolio management
Last published
35 USC § 101: Further clarification of patent subject-matter eligibility.
By
Sara HAINES
, US Patent Agent.
Two recently issued USPTO memorandums further clarify aspects of patent subject-matter eligibility under 35 USC § 101. The Vanda memo1 specifies methods of treatment that should be considered to be patent eligible under step 2A of the Alice/Mayo test2 thereby avoiding any further analysis under step 2B, while the Berkheimer memo3 states that examiners must provide substantiated evidence when additional claim elements are considered to represent well-understood, routine, conventional activity in support of 35 USC § 101 rejections under step 2B.
Published on: 30th Oct 2018
Patent
Patentability of Biological Material
Biomarkers
All publications
Discover the
Life Sciences and Chemistry